Author:
Siegel Lawrence,Gulick Roy M.
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. Bethell R, Lie YS, Parkin NT: In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antivir Chem Chemother 2005, 16:295–302.
2. Francis RJ, Lanclos L, Shiveley L, et al.: Pharmacokinetics of SPD754, a new cytidine analogue, in healthy volunteers. Antivir Ther 2003, 8:S325.
3. Bethell R, Adams J, De Muys J, et al.: Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754 [abstract 138]. Presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco; February 8–11, 2004.
4. Bethell R, Collins P, Holdich T, et al.: In vitro and in vivo antiviral activity of SPD754 against wild-type and NRTI-resistant viruses [abstract WePeA5642]. Presented at the XV International AIDS Conference. Bangkok; July 11–16, 2004.
5. Gu Z, Allard B, de Muys JM, et al.: In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immuno deficiency virus infection. Antimicrob Agents Chemother 2006, 50:625–631.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献